What is Amarin Corporation plc (AMRN)?

Amarin Corporation plc (AMRN) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of AMRN?

The current price of AMRN is $12.09. Prices are updated in real time on Stocks360.

What is AMRN's price-to-earnings (PE) ratio?

AMRN's trailing twelve-month PE ratio is -8.46, based on current price and earnings per share data available on Stocks360.

What is AMRN's market capitalization?

AMRN's market capitalization is $250,054,738.00, placing it in the small-cap tier.

Amarin Corporation plc (AMRN)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - General

$12.09

Market Cap

$250.05M

PE (TTM)

-8.46

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.77

Day Range

$11.72 – $12.17

52-wk Range

$11.25 – $20.57

Avg Volume

N/A

Volume

64.82K

Amarin Corporation plc (AMRN) is a publicly traded company in the Healthcare sector. Latest price: $12.09. Market cap $250.05M. Trailing PE -8.46. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-27 · $19.24 2026-10-26 · $12.09 (-37.16%)

Earnings

Most Recent

Jul 29, 2026

EPS $-0.02 vs est. $-0.01

Missed by $0.01

Next Earnings

Oct 28, 2026

EPS estimate $-0.10

Proprietary Signals

Signal snapshot temporarily unavailable.

About Amarin Corporation plc

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-8.46×
P/S (TTM)	1.34×
P/B	0.57×
P/FCF (TTM)	5.09×
EV / EBITDA	-5.68×
EV / Sales	0.60×
Earnings Yield	-10.77%
Free Cash Flow Yield	19.66%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$111.75M
Revenue (TTM)	$186.16M
Net Income (TTM)	-$26.94M
Free Cash Flow (TTM)	$49.17M
Net Debt	-$138.30M
Working Capital	$438.56M
Gross Margin	41.58%
Operating Margin	-17.91%
Net Margin	-14.57%
Return on Equity	-5.99%
Return on Invested Capital	-7.25%